UPDATE: Pfizer's oral COVID-19 antiviral cuts hospitalization, death by 85%, sending team barreling to FDA Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing push beyond prophylactic vaccines Veterans from GSK's GlycoVaxyn rally up $49M to advance Swiss biotech GlycoEra Sponsored: A New Reference Model for Clinical Trial Recruitment, Enrollment and Retention Success HitGen taps Cambridge Molecular for 'deep learning' drug discovery collab Sponsored: Intranasals in Clinic Now Positioned for $71 Billion Nasal Delivery Market Alphabet launches AI drug discovery venture built on DeepMind's protein-folding expertise Novartis exits 20-year Roche stake, creating a $20.7B question about CEO Vas Narasimhan's next M&A move UnitedHealth-Change Healthcare deal could close in late February Parkinson's gene therapy restores responses to dopamine-boosting drug in mouse models Fierce Pharma Asia—Legend, J&J's CAR-T delay; BeiGene's Brukinsa data; Samsung Biologics CEO interview Chutes & Ladders—Mirati Therapeutics CMO, COO given the boot as FDA filing looms Featured Story | By Nick Paul Taylor Pfizer’s oral COVID-19 antiviral has cut the risk of hospitalization or death by 85% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from the FDA. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Moderna has suffered an early blow to its move beyond prophylactic vaccines, revealing it won’t take the lead candidate in one of its core modalities into phase 2. The mRNA player removed the drug candidate from its pipeline after wrapping up a phase 1 dose-escalation study. read more By Emmy Lucas Veronica Gambillara Fonck, Ph.D., has been one member of a group of scientists that have followed each other across a dizzying landscape of spinoffs and new ventures in vaccines R&D. Now, the team has come together once again to launch Swiss biotech GlycoEra AG with a $49 million series A. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Ben Adams Chinese drug discovery biotech HitGen is teaming up with U.K.-based Cambridge Molecular to better seek out new drugs. read more Sponsored By: Avance Clinical the Australian CRO for global biotechs Australia’s Avance Clinical: how intranasal biotechs can expedite trials with rapid approval processes - including no IND and a 43.5% incentive rebate - to tap $71 billion market read more By Conor Hale The new Isomorphic Laboratories aims to deliver an “AI-first approach” for tackling biopharma research, with the goal of serving as a commercial partner to drugmakers. read more By Angus Liu After 20 years, Novartis is finally shedding its stake in Swiss rival Roche, gaining a handsome return on investment but leaving behind a big question of where CEO Vas Narasimhan plans to spend all the money. read more By Paige Minemyer UnitedHealth Group and Change Healthcare have agreed not to close their pending deal before Feb. 22—though the acquisition could close sooner if the Department of Justice wraps its probe early. read more By Kyle LaHucik Northwestern University researchers found that a gene therapy targeting the region of the brain that houses dopamine-releasing neurons could boost the effectiveness of the widely used Parkinson's drug levodopa in mice. The team also found a a path to diagnosing the disease early. read more By Angus Liu Legend Biotech and Johnson & Johnson have to wait three more months for an FDA decision on their CAR-T medicine. BeiGene's Brukinsa posts competitive frontline leukemia data as key BTK showdown nears. Samsung Biologics' newly minted CEO talks about the CDMO's rapid expansion. And more. read more By Kyle LaHucik Mirati Therapeutics parted ways with its chief medical and operating officers as the biotech gets nearer to asking the FDA to approve its first drug. Moderna's former chief medical officer chooses VC shop OrbiMed as his next stop. Lengo Therapeutics hiring spree doesn't abate as it poaches Turning Point, ex-Pfizer fellow. read more |
| LabConnect is the leader in innovative central laboratory services for advanced therapies. Far more than typical central laboratory support, only LabConnect offers comprehensive, specialized services customizable to meet the unique needs of your complex clinical trials. Connect with us today. |
Resources Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Blue Matter Consulting Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Pharma Meeting Pros Summit November 3-4, 2021 | Atlantic City, NJ & Virtual Fierce Diversity, Equity & Inclusion Summit November 9–10, 2021 | Virtual Event Drug Development Boot Camp® 2021 VIRTUAL November 17-18, 2021 Learn impact of pricing, competitive assessment, epidemiology November 17-18, 2021 | Live & Online Fierce New Product Planning Summit December 1-2, 2021 | Boston, MA Fierce Launch Readiness for Medical Affairs & Communications Teams December 1-2, 2021 | Boston, MA Learn how therapeutics are successfully launched and commercialized December 1-2, 2021 | Live & Online 2nd Annual Symposium on Translational Medicine and Biomanufacturing December 2—3, 2021 Fierce Virtual Clinical Trials Summit December 6-7, 2021 | Philadelphia, PA Fierce JPM Week 2022 January 11, 2022 | San Francisco, CA
January 18-20, 2022 | Virtual Event Virtual European Healthcare Compliance Certificate Program January 24-28, 2022 Fierce Biotech Forum 2022 | Virtual Event Fierce Pharma Drug Safety Summit February 8-9, 2022 | Location TBD May 2022 | Location TBD | 